← DocG Medical Summaries
Top Oncology Research Papers
1.
8.5
Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy.
Overall: A strong randomized phase 3 trial reports a large and precise survival benefit with fewer severe adverse events, supporting meaningful practice change despite open-label conduct and unresolved access and implementation details.
2.
8.2
Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia.
Overall: A large randomized trial found a substantial improvement in event-free survival and fewer severe infectious complications when blinatumomab replaced two chemotherapy cycles, despite increased neurotoxicity and unresolved implementation details.
3.
8.2
Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer.
Overall: Long-term randomized data establish weekly cisplatin as a practical, survival-preserving alternative, although superiority and a clear safety advantage were not demonstrated.
4.
8.1
Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: A Randomized Clinical Trial.
Overall: A strong multicenter randomized trial supports five-fraction SBRT as a convenient option with meaningful quality-of-life advantages, but it does not establish superior disease control.
5.
8.0
Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.
Overall: A mature randomized phase 3 follow-up reports substantial, durable survival benefit without new safety signals, though post hoc modeling, incomplete absolute-effect and toxicity data, and prolonged treatment burden temper certainty and practicality.
6.
7.9
Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.
Overall: A large randomized phase 3 trial found substantial progression-free and overall-survival advantages for talquetamab combinations, balanced against frequent serious toxicity and the practical burden of specialty-administered multidrug therapy.
7.
7.8
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.
Overall: A rigorous randomized trial shows a substantial and sustained delay in progression from ctDNA-guided early switching, with manageable but increased hematologic toxicity and meaningful implementation demands.
8.
7.6
Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.
Overall: This randomized trial shows a substantial event-free survival advantage and fewer serious complications with azacitidine-venetoclax, but phase 2 scale, selected eligibility, and missing overall-survival data temper immediate practice change.
9.
7.5
Selpercatinib in Early-Stage
Overall: A small but rigorous phase 3 trial found a large event-free survival benefit in early-stage RET-driven NSCLC, offset by frequent serious liver-enzyme elevations and absent mature overall-survival data.
10.
7.3
Patient-Level Evaluation of Optimal Margin Width for Lumpectomy in Ductal Carcinoma In Situ: An Analysis of Patients in the National Cancer Database Special Study.
Overall: This large US observational cohort addresses a clinically important recurrence outcome and an easily actionable surgical decision, but residual confounding and the lack of absolute effect estimates limit its stand-alone practice-changing strength.
Score Guide:
9-10 Exceptional
7-8 Strong
5-6 Moderate
3-4 Weak
1-2 Poor
Top papers in other specialties
Emergency MedicineFamily Medicine / General Practice / Primary CareInternal MedicineAllergy & ImmunologyCardiologyDermatologyEndocrinologyGastroenterologyGeneticsGeriatricsHematologyInfectious DiseaseCritical CareNephrologyNeurologyObesityOccupational & Environmental HealthPain MedicinePalliative & Supportive CarePhysical Medicine & RehabilitationPsychiatryPublic HealthPulmonology/RespirologyRheumatologyObstetrics & GynecologyPediatricsAnesthesiologyOphthalmologyOtolaryngology (ENT)OrthopedicsUrologySurgery (Other)Sports MedicineAddiction Medicine